Capitalization 1.89B P/E ratio 2024 *
14.2x
P/E ratio 2025 * 10.4x
Enterprise value 1.55B EV / Sales 2024 *
2.19x
EV / Sales 2025 * 1.56x
Free-Float
58.83%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.96%
1 week-4.12%
Current month+2.96%
1 month-7.00%
3 months+2.10%
6 months+4.39%
Current year+2.41%
More quotes
1 week
31.02
Extreme 31.02
41.61
1 month
31.02
Extreme 31.02
41.61
Current year
28.14
Extreme 28.14
41.61
1 year
22.89
Extreme 22.89
41.61
3 years
18.61
Extreme 18.6112
62.09
5 years
18.61
Extreme 18.6112
62.09
10 years
18.61
Extreme 18.6112
62.09
More quotes
Director TitleAgeSince
Chief Executive Officer 66 2023-01-05
Director of Finance/CFO 54 2021-03-28
Chief Tech/Sci/R&D Officer 53 2024-04-30
Manager TitleAgeSince
Chairman 56 2017-07-24
Director/Board Member 53 2017-08-31
Director/Board Member 59 2016-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+2.96%-4.12%+34.31%-20.77%1.89B
-1.30%-8.26%+41.12%+218.84%736B
+0.76%-1.96%+8.37%+115.38%496B
+0.17%-0.47%+6.58%-3.30%386B
-0.16%+8.36%+42.08%+74.68%360B
-0.43%-2.02%-0.94%+14.45%258B
+1.94%-2.88%+14.68%-25.68%253B
-0.18%-5.03%+6.37%+16.92%221B
+1.80%-3.21%+12.79%+24.27%219B
-0.29%+0.71%+19.74%+48.99%172B
Average +0.53%-1.89%+18.51%+46.38% 310.29B
Weighted average by Cap. +0.04%-2.32%+20.38%+83.34%
See all sector performances
2024 *2025 *
Net sales 711M 839M
Net income 146M 196M
Net Debt -332M -580M
More financial data * Estimated data
Logo Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Employees
246
More about the company
Date Price Change Volume
24-11-01 33.08 $ +2.96% 5,616,157
24-10-31 32.13 $ -4.94% 4,994,924
24-10-30 33.80 $ -18.53% 2,887,537
24-10-29 41.49 $ +16.06% 1,316,605
24-10-28 35.75 $ +3.62% 809,748

Delayed Quote Nasdaq, November 01, 2024 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C-
surperformance-ratings-light-chart HARMONY-BIOSCIENCES-HOLDIMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
33.08USD
Average target price
47.11USD
Spread / Average Target
+42.42%
Consensus